23 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
22 November 2022 - NICE is unable to make a recommendation on the use of tisagenlecleucel for the treatment of adults ...
10 November 2022 - The outcome from Janssen's application requesting the public funding of ciltacabtagene autoleucel for the treatment of ...
7 November 2022 - ALETA-001 was developed to address the urgent unmet need of patient relapse after CD19 targeted CAR ...
4 November 2022 - The US FDA laid out its recommendations for sponsors to study multiple versions of a cellular or ...
27 October 2022 - MT-101 is the first mRNA engineered CAR monocyte therapy to be dosed in humans. ...
18 October 2022 - CARsgen Therapeutics announces that the NMPA of China has accepted the new drug application for zevorcabtagene autoleucel ...
17 October 2022 - First treatment in 30 years to improve upon standard care for second-line treatment of DLBCL. ...
14 October 2022 - Ebvallo on track to be the first ever allogeneic T-cell therapy approved. ...
29 September 2022 - EMA is launching a pilot to support the translation of basic research developments into medicines that could ...
28 September 2022 - CRISPR Therapeutics today announced that the US FDA granted regenerative medicine advanced therapy designation to CTX130, ...
16 September 2022 - Positive opinion based on landmark ZUMA-7 study in which 41% of patients demonstrated event-free survival at ...
1 September 2022 - Reimbursement in Japan will be similar to that of pricing in the United States. ...
31 August 2022 - New designation may expedite FDA review and potential approval to address this life-threatening heart condition affecting ...
25 August 2022 - First TIL therapy BLA submission initiated with U.S. FDA. ...